Monoclonal Antibody Infusion Physician Portal

ACMH can administer available monoclonal antibody treatments for COVID-19 positive patients who meet specific criteria and for whom the antibodies may be an effective treatment.

ACMH is pleased to be among the health care organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.

This one-time infusion may help keep certain individuals with mild to moderate COVID-19 from progressing in their illness to severe disease and may make it less likely that a patient would need to go to the emergency department or need hospitalization.

ACMH is using monoclonal antibody infusion treatment products in the outpatient infusion center located at the Health and Wellness Education Pavilion, 79 Glade Drive, Kittanning, PA.

For Providers: Ordering Monoclonal Antibody Infusion for Patients

If you would like to order the Monoclonal Antibody Infusion for a patient, download this PROVIDER ORDER PACKET

Complete and fax the forms to 724-543-8855.

Call 724-543-8131 to schedule your patient.



Monoclonal Antibody Infusion: Indications for Use


  • Patient must still be symptomatic and within the established timeframe
  • If symptoms have resolved or if the patient now requires new or escalating oxygen therapy, do not refer the patient for treatment

Confirmed COVID-19 positive patients AND mild symptoms* for ≤ 10 days AND one of the following criteria:

  • Age ≥65 years
  • BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts
  • Pregnancy
  • Chronic Lung Disease (COPD, asthma, pulmonary hypertension, cystic fibrosis)
  • Chronic kidney disease
  • Cardiovascular disease (including congenital heart disease, hypertension)
  • Diabetes
  • Down syndrome
  • Dementia
  • Liver disease
  • Current or former smoker
  • Current or history of substance abuse
  • Immunosuppressive disease or immunosuppressive treatment
  • History of stroke or cerebrovascular disease
  • Chronic lung disease
  • Sickle cell disease
  • Neurodevelopmental disorders or other conditions that confer medical complexity
  • Having a medical-related technological dependence (e.g., tracheostomy, gastrostomy)

*Symptoms include: Fever, cough, sore throat, malaise, headache, muscle pain, GI symptoms, or shortness of breath with exertion.

Monoclonal Antibody Infusion: Limitations of Use

Not authorized for use in patients:

  • Who are hospitalized due to COVID-19
  • Who require O2 therapy due to COVID-19
  • Who require an increase in baseline O2 flow rate due to COVID-19

Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.

There is limited experience treating pregnant women or breastfeeding mothers with bamlanivimab/etesevimab. For a mother and unborn baby, the benefit of receiving bamlanivimab/etesevimab may be greater than the risk from the treatment. If your patient is pregnant or breastfeeding, discuss options and specific situation with the patient and health care provider.

Monoclonal Antibody Infusion: Infusion Considerations

With many infusions, there is a risk of allergic reaction to the infusion, albeit reactions to these medications requiring discontinuation are very rare. The infusion center has trained staff and appropriate medications to address any reaction, including: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.

COVID-19 Vaccines and Monoclonal Antibody Infusion

Per the CDC, COVID-19 vaccination should be deferred for at least 90 days after receiving monoclonal antibody infusion.

Persons who have received a COVID-19 vaccine may receive monoclonal antibody at any point after vaccination, if the patient is a candidate based on COVID-19 disease.

Patient and Caregiver Information

Click HERE to read a Fact Sheet for Patients, Parents and Caregivers on the Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab for Coronavirus Disease 2019 (COVID-19).